CN115417816A - Preparation method of 3,6-dibromo-1-chloro-isoquinoline - Google Patents

Preparation method of 3,6-dibromo-1-chloro-isoquinoline Download PDF

Info

Publication number
CN115417816A
CN115417816A CN202211081311.6A CN202211081311A CN115417816A CN 115417816 A CN115417816 A CN 115417816A CN 202211081311 A CN202211081311 A CN 202211081311A CN 115417816 A CN115417816 A CN 115417816A
Authority
CN
China
Prior art keywords
reaction
nitrite
compound
dissolving
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202211081311.6A
Other languages
Chinese (zh)
Other versions
CN115417816B (en
Inventor
朱宇
丁宗苍
叶紫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ogenic Materials Suzhou Co ltd
Jiangsu Nata Opto Electronic Material Co Ltd
Original Assignee
Jiangsu Nata Opto Electronic Material Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Nata Opto Electronic Material Co Ltd filed Critical Jiangsu Nata Opto Electronic Material Co Ltd
Priority to CN202211081311.6A priority Critical patent/CN115417816B/en
Publication of CN115417816A publication Critical patent/CN115417816A/en
Application granted granted Critical
Publication of CN115417816B publication Critical patent/CN115417816B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Abstract

A preparation method of 3,6-dibromo-1-chloro-isoquinoline, which belongs to the field of organic synthesis and comprises the following steps:

Description

Preparation method of 3,6-dibromo-1-chloro-isoquinoline
Technical Field
The invention relates to the field of organic synthesis, and in particular relates to a preparation method of 3,6-dibromo-1-chloro-isoquinoline.
Background
3,6-dibromo-1-chloro-isoquinoline is a key intermediate in the synthesis process of OLED molecular materials. The existing 3,6-dibromo-1-chloro-isoquinoline synthesis method has the disadvantages of more general process steps, complex process, lower yield of target products and more byproducts. How to develop a 3,6-dibromo-1-chloro-isoquinoline synthesis method with simple process, high yield and less side reactions is a difficult problem which is eagerly solved in the industry.
Disclosure of Invention
In order to solve the problems in the prior art, the invention designs a new route for synthesizing 3,6-dibromo-1-chloro-isoquinoline, and the new route has the advantages of simple process, mild conditions, high yield and few side reactions, and is suitable for industrial production.
The technical scheme of the invention is as follows:
a preparation method of 3,6-dibromo-1-chloro-isoquinoline (I),
Figure BDA0003832574060000011
which comprises the following steps:
s1, weighing 5-bromo-1-indanone W001, dissolving in an alcohol solvent, slowly adding concentrated hydrochloric acid, dropwise adding nitrite or nitrite at about 30-50 ℃, uniformly stirring, reacting at about 30-50 ℃, cooling to room temperature after reaction, and filtering to obtain white floccule W002
Figure BDA0003832574060000012
S2, dissolving a compound W002 in a halogenated hydrocarbon solvent, introducing HCl gas in advance to prepare a saturated solution, adding a brominating reagent in batches at the temperature of about 0 ℃, uniformly stirring, reacting at the temperature of about 70-90 ℃, and performing post-treatment after the reaction to obtain a compound W003
Figure BDA0003832574060000021
S3, dissolving the compound W003 in a sodium methoxide/alcohol solvent or an alkali metal alkoxide/hydrocarbon solvent, uniformly stirring, reacting at 50-85 ℃, and carrying out post-treatment after the reaction to obtain solid W004
Figure BDA0003832574060000022
Wherein R is an alkyl group, such as C1-C6 alkyl, methyl, ethyl, propyl, butyl or tert-butyl;
s4, dissolving the crude product of the compound W004 in a halogenated hydrocarbon solvent, adding Lewis acid below 0 ℃ for reaction at room temperature, quenching the reaction by using a saturated alkali solution at 0 ℃ after the reaction is finished, and performing post-treatment to obtain solid W005
Figure BDA0003832574060000023
S5, dissolving W005 in a chlorinating agent, uniformly stirring, reacting at the temperature of about 100 ℃ to about 130 ℃, cooling to room temperature after the reaction is finished, distilling under reduced pressure to remove the chlorinating agent, and carrying out post-treatment to obtain a white solid
Figure BDA0003832574060000024
In some embodiments, the nitrite or nitrite ester in step S1 is selected from sodium nitrite, isobutyl nitrite, tert-butyl nitrite, and like agents.
In some embodiments, the molar ratio of the brominating reagent to compound W002 in S2 step is about 2.0 to about 5.0, and in some embodiments, the molar ratio of the brominating reagent to compound W002 is about 3.0. In some embodiments, the brominating reagent is selected from POBr 3 Or PBr 5
In some embodiments, the halogenated hydrocarbon solvent in step S2 or step S4 is selected from one or more of dichloroethane DCE, dichloromethane, carbon tetrachloride, or 1,2-dichloroethane.
In some embodiments, the S2 step post-processing comprises: cooling to room temperature, concentrating under reduced pressure and carefully pouring the residue into a mixture of ice and water to quench, filtering, extracting the filtrate with ethyl acetate, drying, concentrating, and purifying with a column to give a grey solid W003
In some embodiments, the alcoholic solvent of step S3 is selected from methanol, ethanol, isopropanol, tert-butanol, or a combination thereof; the alkali metal alkoxide/aprotic solvent is selected from potassium t-butoxide, sodium methoxide, sodium isopropoxide or a similar active base or a combination thereof, and the aprotic solvent is selected from benzene, toluene, xylene or a combination thereof, and in some embodiments, the alkali metal alkoxide/aprotic solvent is a combination of toluene and t-Bu 0K.
In some embodiments, in step S4, the lewis acid is selected from PCl 3 、BBr 3 、AlCl 3 、BF 3 Or BCl 3 Or a combination thereof; the chlorinating agent is selectedself-POCl 3 、PCl 5
In some embodiments, the amount of alkali metal alkoxide used in the process may be in an equivalent (molar) or excess (molar) relative to the compound of formula (W003), and in some embodiments, from 1 to 5 equivalents. And in other embodiments from 2 to 5 equivalents. In other embodiments from 3 to 5 equivalents, and in certain embodiments from 1.1 to 2.5 equivalents.
In some embodiments, the S1 step reaction temperature is about 35 ℃ or about 40 ℃, or about 45 ℃, or about 50 ℃; the reaction temperature in the step S2 is about 75 ℃, or about 78 ℃, or 80 ℃, or about 85 ℃; the reaction temperature of the S3 step is 55 ℃, or about 60 ℃, or about 65 ℃, or about 70 ℃, or about 75 ℃; the reaction temperature of the S4 step is about 20 ℃, or about 25 ℃, or about 30 ℃, or about 32 ℃, or about 35 ℃; the reaction temperature in the step S4 is about 110 ℃ or about 115 ℃, or about 120 ℃ or about 130 ℃ or about 135 ℃.
The methods described herein may also include known purification methods such as crystallization, chromatography (liquid and gas phases and the like), extraction, distillation, trituration, and reverse phase HPLC, among others. The reaction conditions such as temperature, reaction time, pressure and gas (e.g., inert gas, air) may be appropriately adjusted depending on the reaction.
The invention has the advantages that:
the invention adopts a brand new synthesis route to synthesize 3,6-dibromo-1-chlorine-isoquinoline (I), and related intermediates are all solid, so that the post-treatment is simple and convenient, and the method is suitable for industrial production; the total yield of five steps is up to more than 30%.
Detailed Description
In order to make the technical solutions of the present invention better understood by those skilled in the art, the following further discloses some non-limiting examples to further explain the present invention in detail.
The starting materials and reagents used in the present invention can be prepared by known methods or can be commercially available.
Example 1 a method of making 3,6-dibromo-1-chloro-isoquinoline includes the steps of:
s1, weighing 5-bromo-1-indanone W001 (500g, 2369mmol) and dissolving inMeOH (4500 mL), then con. HCI (213 mL) was added slowly, butyl nitrite (308.3 mL) was added dropwise at 40 ℃, stirred well and reacted for 2.5h at 40 ℃. After completion of the reaction, the reaction mixture was cooled to room temperature and filtered to obtain W002 (421 g, yield 59.07%) as a white floc. Characterization of W002 results 1H NMR (400mhz, dmso-d 6) δ 12.73 (s, 1H), 7.90 (p, J =1.1hz, 1h), 7.68 (d, J =1.1hz, 2h), 3.79 (d, J =1.0hz, 2h), MS (ESI) m/z:239.97[ 2 ], [ C ] 9 H 6 BrNO 2 + H] + .
Figure BDA0003832574060000041
S2, taking W002 (23.9g, 100mmol) to dissolve in DCE (500 mL, prepared into saturated solution by introducing HCl gas in advance), and adding POBr in portions at 0 DEG C 3 (60g, 200mmol), stirring well and reacting at 80 ℃ for 2h. After cooling to room temperature, concentration under reduced pressure and careful pouring of the residue into a mixture of ice and water to quench, after filtration the filtrate was extracted with ethyl acetate, dried, concentrated and after column purification afforded W003 (22.1 g, yield 61%) as a grey solid. Characterization of W003 results 1H NMR (400mhz, dmso-d 6) 68.34 (d, J =2.0hz, 1h), 8.24 (d, J =0.8hz, 1h), 8.10 (dt, J = 9.1,0.7hz, 1h), 7.97 (dd, J =9.0,1.9hz, 1h). MS (ESI) m/z:363.80[ C ] 9 H 4 Br 3 N + H] + .
Figure BDA0003832574060000042
S3, W003 (0.365g, 1mmol) was dissolved in MeOH (2 mL), and sodium methoxide (0.27g, 5mmol) was added thereto, and the mixture was stirred uniformly and reacted at 70 ℃ for 2 hours. After cooling to room temperature the MeOH was distilled off under reduced pressure and the resulting residue was extracted with ethyl acetate, washed once with water and saturated brine respectively, the organic phase was dried, filtered and concentrated to give W004 (0.25 g, crude product) as a brown solid. Characterization of W004 results 1H NMR (400mhz, chloroform-d) 68.07 (dt, J =8.8, 0.7hz, 1h), 7.83 (d, J =1.9hz, 1h), 7.63 (dd, J =8.9,1.9hz, 1h), 7.37 (d, J =0.8hz, 1h), 7.29 (s, 1H), 4.16(s,3H).MS(ESI)m/z:315.90[C 10 H 7 Br 2 NO + H] + .
Figure BDA0003832574060000051
S4, taking W004 (0.25 g, crude product) and dissolving in CH 2 Cl 2 (2 mL), BBr was added at 0 deg.C 3 (2 mL) and reacted at room temperature for 1h. After the reaction, a saturated sodium bicarbonate solution was added at 0 ℃ to quench the reaction, and the reaction solution was diluted with dichloromethane, extracted with a saturated saline solution, dried, filtered, and concentrated to obtain a brown yellow solid W006 (0.2 g, crude product). Characterization results MS (ESI) m/z:301.88[ 2 ], [ C ] 9 H 5 Br 2 NO + H] + .
Figure BDA0003832574060000052
S5, dissolving W006 (17g, 56.5mmol) in POCl 3 (60 mL), stirred well and reacted at 120 ℃ for 2h. Cooling to room temperature, and distilling under reduced pressure to remove POCl 3 The obtained residue was extracted with ethyl acetate, washed with saturated brine and saturated aqueous sodium bicarbonate solution, respectively, and the organic phase was dried, filtered, concentrated, and column-purified to obtain OLED2 (11.75 g, yield 64.02%, purity 98.5%, HPLC purity) as a white solid. Characterization results for OLED2 1H NMR (500mhz, dmso-d 6) δ 8.38 (d, J =2.0hz, 1h), 8.25 (d, J =0.8hz, 1h), 8.19 (d, J =9.0hz, 1h), 7.99 (dd, J =9.0,1.9hz, 1h). MS (ESI) m/z:319.85[ 2 ], [ C ] 9 H 4 Br 2 CIN + H] + .
Figure BDA0003832574060000053
Example 2 a method of making 3,6-dibromo-1-chloro-isoquinoline includes the steps of:
s1 is the same as step S1 in example 1.
S2 is the same as step S2 in example 1.
S3, dissolving W003 (0.732g, 2mmol) in toluene (5 mL), adding t-BuOK (0.56g, 5mmol) at 0 ℃, stirring uniformly, reacting at 110 ℃ for 2H, cooling to room temperature, concentrating under reduced pressure, extracting the obtained residue with ethyl acetate, drying, filtering, concentrating, and purifying with a column to obtain W005 (0.4 g, yield 56%) as a yellow solid, W005 (400MHz, DMSO-d 6), delta 8.14 (d, J =1.9Hz, 1H), 8.00 (dt, J =8.9,0.7Hz, 1H), 7.75 (dd, J =8.9,2.0Hz, 1H), 7.63 (d, J =0.8Hz, 1H), 1.67 (S, 10H), MS (ESI) m/z:357.94 [ C.5363 [ [ C, 10H ] ], ] 13 H 13 Br 2 NO + H] + .
Figure BDA0003832574060000061
S4, W005 (0.183g, 0.5 mmol) was dissolved in HCOOH (3 mL) and reacted at room temperature for 0.5h. After completion of the reaction, the solvent was directly removed by concentration, and the residue was purified by column chromatography to obtain W006 as a yellow solid (0.1 g, yield 66%). Characterization results MS (ESI) m/z:301.88[ 2 ], [ C ] 9 H 5 Br 2 NO + H] + .
Figure BDA0003832574060000062
Example 3 a method of making 3,6-dibromo-1-chloro-isoquinoline includes the steps of:
s1 is the same as step S1 in example 1.
S2, taking W002 (23.9g, 100mmol) to dissolve in dried dichloromethane (1L), adding PBr5 (64.57 g, 150mmol) at 0 ℃, stirring uniformly, and reacting for 16h at 30 ℃. The dichloromethane was removed by concentration under reduced pressure, the obtained residue was redissolved with dioxane (1L), dried at 10 ℃ to obtain HBr gas, the gas was stopped when the reaction solution changed from beige to brown, reacted at 30 ℃ for 16 hours, and then reacted at 60 ℃ for 2 hours. Cooling the reaction solution to room temperature, extracting with ethyl acetate, washing with saturated saline water and saturated sodium bicarbonate water solution, drying the organic phase, filtering, concentrating, and pulping with n-hexane to obtain brown yellowW006 as a colored solid (17 g, 56.5% yield). Characterization of W006 results 1H NMR (500 mhz, dmso-d 6) δ 12.35 (s, 1H), 8.04 (d, J =8.5hz, 1h), 7.91 (d, J =2.0hz, 1h), 7.65 (dd, J =8.5, 2.0hz, 1h), 6.88 (s, 1H). MS (ESI) m/z:301.88[ 2 ], [ C ] 9 H 5 Br 2 NO+H]+.
Figure BDA0003832574060000063
S3 is the same as step S5 in example 1.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (10)

1. A preparation method of 3,6-dibromo-1-chloro-isoquinoline (I),
Figure FDA0003832574050000011
which comprises the following steps:
s1, weighing 5-bromo-1-indanone W001, dissolving in an alcohol solvent, slowly adding concentrated hydrochloric acid, dropwise adding nitrite or nitrite at about 30-50 ℃, uniformly stirring, reacting at about 30-50 ℃, cooling to room temperature after reaction, and filtering to obtain white floccule W002
Figure FDA0003832574050000012
S2, dissolving a compound W002 in a halogenated hydrocarbon solvent, introducing HCl gas in advance to prepare a saturated solution, adding a brominating reagent in batches at the temperature of about 0 ℃, uniformly stirring, reacting at the temperature of about 70-80 ℃, and performing post-treatment after the reaction to obtain a compound W003
Figure FDA0003832574050000013
S3, dissolving the compound W003 in an alcohol solvent/sodium methoxide or alkali metal alkoxide/hydrocarbon solvent, uniformly stirring, reacting at 50-85 ℃, and treating after the reaction is finished to obtain solid W004
Figure FDA0003832574050000014
Wherein R is an alkyl group, such as C1-C6 alkyl, methyl, ethyl, propyl, butyl or tert-butyl;
s4, dissolving the crude product of the compound W004 in a halogenated hydrocarbon solvent, adding Lewis acid below 0 ℃ for reaction at room temperature, quenching the reaction by using a saturated alkali solution at 0 ℃ after the reaction is finished, and performing post-treatment to obtain solid W005
Figure FDA0003832574050000015
S5, dissolving W005 in a chlorinating agent, uniformly stirring, reacting at the temperature of about 100 ℃ to about 130 ℃, cooling to room temperature after the reaction is finished, distilling under reduced pressure to remove the chlorinating agent, and carrying out post-treatment to obtain a white solid
Figure FDA0003832574050000021
2. The method according to claim 1, wherein said nitrite or nitrite ester in step S1 is selected from the group consisting of sodium nitrite, isobutyl nitrite, and tert-butyl nitrite.
3. The method according to claim 1, wherein the molar ratio of the brominating reagent to the compound W002 in the S2 step is 2.0 to 5.0.
4. A method according to claim 3 wherein the molar ratio of said brominating reagent to compound W002 is 3.0.
5. The process according to claim 3 or 4, wherein the brominating reagent is POBr 3 Or PBr 5
6. The method according to claim 1, wherein the halogenated hydrocarbon solvent in step S2 or S4 is one or more selected from the group consisting of dichloroethane DCE, dichloromethane, carbon tetrachloride and 1,2-dichloroethane.
7. The method of claim 1, wherein the step S2 post-processing comprises: after cooling to room temperature, concentration under reduced pressure and quenching by careful pouring of the residue into an ice-water mixture, filtration and extraction of the filtrate with ethyl acetate, drying, concentration and column purification gave W003 as a grey solid.
8. The method according to claim 1, wherein the alcoholic solvent in step S3 is selected from methanol, ethanol, isopropanol, tert-butanol, and combinations thereof.
9. The method of claim 1, wherein the alkali metal alkoxide/aprotic solvent is selected from potassium t-butoxide, sodium methoxide, sodium isopropoxide, or a similar active base or a combination thereof, and the aprotic solvent is selected from benzene, toluene, xylene, or a combination thereof, or the alkali metal alkoxide/aprotic solvent is a combination of toluene and t-BuOK.
10. The method according to claim 1, wherein the Lewis acid is selected from PCl in step S4 3 、BBr 3 、AlCl 3 、BF 3 Or BCl 3 Or a combination thereof; the chlorinating agent is selected from POCl 3 Or PCl 3
CN202211081311.6A 2022-09-05 2022-09-05 Preparation method of 3, 6-dibromo-1-chloro-isoquinoline Active CN115417816B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211081311.6A CN115417816B (en) 2022-09-05 2022-09-05 Preparation method of 3, 6-dibromo-1-chloro-isoquinoline

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211081311.6A CN115417816B (en) 2022-09-05 2022-09-05 Preparation method of 3, 6-dibromo-1-chloro-isoquinoline

Publications (2)

Publication Number Publication Date
CN115417816A true CN115417816A (en) 2022-12-02
CN115417816B CN115417816B (en) 2024-01-26

Family

ID=84201859

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211081311.6A Active CN115417816B (en) 2022-09-05 2022-09-05 Preparation method of 3, 6-dibromo-1-chloro-isoquinoline

Country Status (1)

Country Link
CN (1) CN115417816B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115572262A (en) * 2022-10-27 2023-01-06 厦门沃克沃德医药科技有限公司 Isoquinoline derivative and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CN105017152A (en) * 2015-07-17 2015-11-04 北京六合宁远科技有限公司 Preparation method of 3-chloro(bromo)-6-nitroisoquinoline
US20170119912A1 (en) * 2014-06-13 2017-05-04 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrillary
CN108929270A (en) * 2018-08-15 2018-12-04 上海罕道医药科技有限公司 A kind of synthesis of the disubstituted nitrogenous heterocyclic aminated compounds of pharmaceutical intermediate
CN114980975A (en) * 2019-12-23 2022-08-30 Ucb生物制药有限责任公司 Dihydrocyclopentaisoquinoline sulfonamide derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20170119912A1 (en) * 2014-06-13 2017-05-04 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrillary
CN105017152A (en) * 2015-07-17 2015-11-04 北京六合宁远科技有限公司 Preparation method of 3-chloro(bromo)-6-nitroisoquinoline
CN108929270A (en) * 2018-08-15 2018-12-04 上海罕道医药科技有限公司 A kind of synthesis of the disubstituted nitrogenous heterocyclic aminated compounds of pharmaceutical intermediate
CN114980975A (en) * 2019-12-23 2022-08-30 Ucb生物制药有限责任公司 Dihydrocyclopentaisoquinoline sulfonamide derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HELEN A. PAINE, ET AL.: "Exploration of the nicotinamide-binding site of the tankyrases, identifying 3-arylisoquinolin-1-ones as potent and selective inhibitors in vitro", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 23, pages 5891 - 5908, XP055417167, DOI: 10.1016/j.bmc.2015.06.061 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115572262A (en) * 2022-10-27 2023-01-06 厦门沃克沃德医药科技有限公司 Isoquinoline derivative and preparation method thereof

Also Published As

Publication number Publication date
CN115417816B (en) 2024-01-26

Similar Documents

Publication Publication Date Title
CN106866553B (en) Synthesis method of Favipiravir
JP5656952B2 (en) Piperazine derivative oxalate crystals
CN106928227A (en) The synthetic method and its midbody compound of Entecavir
CN114539048B (en) Carlong anhydride intermediate and preparation method of Carlong anhydride
CN115417816B (en) Preparation method of 3, 6-dibromo-1-chloro-isoquinoline
JP2016503812A (en) Process for preparing 1-([1,3] dioxolan-4-ylmethyl) -1H-pyrazol-3-ylamine
CN115417802A (en) Preparation method of sepiatinib and intermediate thereof
CN111793016A (en) Preparation method of larotinib intermediate and intermediate compound
KR20180116371A (en) Process for producing 4-alkoxy-3-hydroxypicolic acid
CN107216332B (en) The synthetic method of 5 (6H) formic acid base ester of tert-butyl -7- methylol -7,8- dihydro 4H pyrazolo diazepine
CN111675660B (en) Preparation method for synthesizing palbociclib intermediate and method for synthesizing palbociclib
CN108623602A (en) A method of prepare and purify and replaces Buddhist nun according to Shandong
WO2004005241A1 (en) Process for producing optically active amide
ZA200503239B (en) Process for production of an acetylenic compound
GB1597428A (en) Manufacture of pyridoxin
CN110746367B (en) Synthesis method of 1,2, 4-triazole-3-methyl carboxylate
CN113816955B (en) RET kinase inhibitor intermediate and preparation method thereof
CN108503583B (en) Alkylation method of nitrogen-hydrogen-containing compound and application thereof
CN111004141B (en) New method for synthesizing nintedanib intermediate 2-chloro-N-methyl-N- (4-nitrophenyl) acetamide
CN114560862A (en) Synthesis method of pyrrolo [1,2-A ] quinoxaline-4 (5H) -ketone and derivative thereof
KR100654923B1 (en) Process for continuously preparing high purity chiral amide compound
CN117700344A (en) Preparation method of levetiracetam
US10150731B2 (en) Method for preparing 4-cyanopiperidine hydrochloride
CN105646154B (en) Synthesis and deprotection method of novel protecting group-containing 3-allylphenol derivative
KR100448641B1 (en) Method for producing phenyl propionic acid derivatives from 2-phenylpropionic acid by simple processing steps with high yield

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230824

Address after: 215000 NO.67, Pingsheng Road, Shengpu, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Applicant after: JIANGSU NATA OPTO-ELECTRONIC MATERIAL Co.,Ltd.

Applicant after: Ogenic Materials (Suzhou) Co.,Ltd.

Address before: 215000 NO.67, Pingsheng Road, Shengpu, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Applicant before: JIANGSU NATA OPTO-ELECTRONIC MATERIAL Co.,Ltd.

GR01 Patent grant
GR01 Patent grant